As the British Generic Manufacturers Association continues to pursue legal action seeking a seat at the table as part of UK government negotiations over the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) rebate mechanism, the off-patent industry body has gone public with its proposals, setting out a series of changes that it believes need to be made to reform the “out of control” VPAS scheme.
With the BGMA excluded from full participation in the current negotiations for the new scheme – which will run from 2024 to 2028 – it has made a bid for judicial review of the government’s decision to exclude the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?